Is Artiva Biotherapeutics, Inc. Common Stock (ARTV) overvalued? · $37.3M cap
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
This page asks whether Artiva Biotherapeutics, Inc. Common Stock (ARTV) looks expensive on cached numbers — not a short thesis.
Latest reported ARTV revenue for 2025-12-31 was $0. Net income was -$83.9M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. ARTV currently screens at market cap $37.3M.
ARTV currently screens at market cap $37.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ARTV 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ARTV stock page for the full model, not this heading.
Not investment advice.